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Background: Osteoarthritis of the knee is a major cause of disability among adults. Electro-acupuncture is considered a
potentially useful treatment for osteoarthritis. The purpose of this study is to assess the efficacy of electro-acupuncture on
pain control, pain perception, plasma cortisol and beta-endorphin levels, patient-perceived quality of life, and
pain medication use in patients with chronic knee pain.
Methods/design: This study is a placebo-controlled, randomized, double-blind, parallel design trial. One hundred sixty
out-patients who are more than 50 years old and who have osteoarthritis of the knee will be recruited from the island of
Mallorca, Spain. Each participant will be randomly placed into one of two groups: (sham) electro-acupuncture
non-insertion technique and real electro-acupuncture.
Acupuncture treatments will be the Traditional Chinese Medicine type. The patients will be evaluated after a
period of 1 month (with two weekly sessions), 3 months (with one monthly session), 6 months (with one session every
45 days), and 1 year later with follow-up sessions at the end of the study (with one session every 2 months).
The primary outcomes will be based on the observed changes from the baseline of the visual analogue scale (VAS) and
the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) for pain measured at 12 weeks after the
end of treatment.
Also to be included in the study are the possible changes in the secondary efficacy variables from baseline as assessed by
the Short Form 36 version 2 health survey (patient-perceived quality of life), patient plasma cortisol and beta-endorphin
levels at the different treatment stages, the Goldberg Anxiety and Depression Scale, pain medication use,
functional capacity and stiffness (WOMAC subscales), and a VAS. These variables will be assessed at 1 month, 3
months, 6 months, and 1 year after study commencement.
Discussion: The findings from this study will help to determine whether electro-acupuncture is effective for
chronic knee pain management in older people and whether electro-acupuncture can deliver results for the
improvement of pain relief, stiffness, and disability. The study will therefore be a major step toward understanding the
roles of the hypothalamic-pituitary-adrenal axis and the endogenous opioid system in the effectiveness of
electro-acupuncture for chronic pain.
Trial registration: ClinicalTrials.gov identifier NCT02299713 (11 Nov. 2014).
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Osteoarthritis (OA) is the most common form of arthritis
[1, 2]. Its prevalence is greater among women than men
[3, 4]. Several factors contribute to the risk of OA, includ-
ing age, gender, genetics, behavioral influences, obesity, in-
jury, and reduced muscular strength [5]. Significant
consequences of OA are activity limitations, reduced par-
ticipation in work and social activities, and mental distress.
The most recent clinical guidelines based upon evi-
dence from the UK National Institute of Clinical Excel-
lence [6] and the Osteoarthritis Research International
(OARSI) suggest that the treatment for OA be multidis-
ciplinary in nature and consider non-pharmacological
treatment (such as education, aerobic and resistance ex-
ercises, and weight loss) as well as pharmacological
treatment options (paracetamol) when an additional
treatment is required. In an OARSI systematic review,
five of the eight guidelines considered acupuncture to be
one of the 12 possible non-pharmacological therapy mo-
dalities for OA [7].
Acupuncture has been demonstrated to be a safe treat-
ment with a low risk of serious side effects [8–12]. OA
guidelines [13, 14] emphasize treatment safety as an im-
portant issue, especially when the therapeutic agents for
elderly patients with knee OA and comorbidities are con-
current drugs that could have serious, life-threatening
interactions.
Acupuncture could be used to explain the roles that
the hypothalamic-pituitary-adrenal (HPA) axis and the
endogenous opioid (EO) system play as important medi-
ators of pain, the stress response, and other stimuli [15].
Recent neuroimaging studies by positron emission tom-
ography have shown that the relationship between the
neurochemical imbalance in the EO system [16] and the
long-term pain relief produced by acupuncture practice
has the opposite results of those observed with placebo
(sham) acupuncture and that only acupuncture exerts a
long-term effect through the EO system [17].
The effect of acupuncture on the HPA system is far from
clear. Although cortisol release is one of the consequences
of HPA system activation, different studies have shown
opposite responses of cortisol release in response to acu-
puncture. One mediating factor may be the presence or ab-
sence of anxiety and depression, which are known to
predict the onset and severity of chronic pain [18].
Although many studies have demonstrated the efficacy
of acupuncture in the treatment of OA-associated knee
pain [19], only one study [20] demonstrates the effective-
ness of electro-acupuncture (EA) for pain reduction that
includes the indicative reduced cortisol levels and elevated
blood beta-endorphins within the same patient group. It
would be of great interest to determine whether the lack
of these kinds of results could be masked by interfering
factors such as anxiety and depression.When acupuncture was compared with some control
groups (waiting list and control groups with active treat-
ment), the positive effects reached the threshold of clin-
ical relevance. Moreover, the only non-pharmacological
therapeutic treatment for OA shown to reduce pain and
improve physical function was exercise, and this treat-
ment either closely met or exceeded the threshold for
clinical relevance [21].
Although many studies show the efficacy of acupunc-
ture for OA pain, the lack of a common methodology
for the trial design complicates the possibility of com-
paring the respective results in order to determine treat-
ment efficacy.
In this work, we have collected the following methodo-
logical suggestions for acupuncture studies that would
minimize the design biases: the number of patients re-
cruited to achieve the significant differences, treatment
number, long-term treatment [22, 23], recruitment blind-
ing method, EA use [24, 25], assessment of patient percep-
tions about the type of technique used before and after
treatment [26], the objective and subjective assessment of
the technique, and finally the use of sham with no needle
penetration (a non-penetrating sham control). Thus, our
aim is to apply these methods to verify the effectiveness of
acupuncture for OA pain. Furthermore, our placebo use
would permit the validation of the hypothesis.
Additionally, the current economic reality that dictates
the need to develop favorable cost-benefit therapies for
both patients and the health-care system should not be
overlooked, and acupuncture is a cost-effective therapy
for the treatment of knee OA [27].
Finally, a great deal of evidence indicates that various
possible physiological mechanisms explain how acu-
puncture may provide pain relief, and these indicate that
further research is needed to clarify the interrelationship
and regulation of these mechanisms.
Although cortisol release is one of the consequences of
HPA system activation, some studies have shown responses
opposite to the cortisol release produced by acupuncture
practice. Normal individuals show opposite cortisol re-
sponses to those with chronic pain conditions. This sug-
gests that if the HPA axis contributes to the efficacy of
acupuncture, its role is more complex than simply deacti-
vating this system. Rather the contribution may depend on
the population being studied. One of the objectives of this
study is to provide more data to elucidate possible mecha-
nisms of action and to show correlations between reduc-
tions in pain and changes in hormonal markers of HPA
axis function. This will aid in establishing whether changes
in HPA axis are causal or merely epiphenomenal in treat-
ment efficacy.
This following study is a project to assess the effective-
ness of EA for the treatment of common pathologies
that involve chronic OA pain in knee. Additionally, it
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Patients who receive EA will have, to some degree, bet-
ter pain control than non-treated patients.
Operative hypothesis
Patients who receive EA will have a measured basal pain
perception that is three points less on the visual
analogue scale (VAS) after EA treatment in comparison
with non-treated patients.
Statistical hypothesis
Practice of EA will result in a statistically significant




This study proposes a randomized, double-blind,
placebo-controlled, pre- and post-test, parallel design
clinical trial which conforms to the CONSORT (Con-
solidated Standards of Reporting Trials) [28] and
STRICTA (Standards for Reporting Interventions in
Clinical Trials of Acupuncture) guidelines [29] for
acupuncture studies (Fig. 1).
Participants
Participants will be selected from a population with
knee chronic pain caused by OA (>3 months in dur-
ation), from the communities of the island of Mallorca
(Balearic Islands, Spain). These participants will be re-
cruited in the outpatient clinics of the island’s hospi-
tals and advertisements in local newspapers and
through the hospital website (http://www.hsll.es). Adver-
tisements for patient recruitment will not specify acupunc-
ture as one of the treatments being investigated or offered.
Doctors from the trauma services of local hospitals will be
invited to screen patients. The clinical trial will be per-
formed by the Pain Unit at Son Llàtzer Hospital,
Palma de Mallorca.
A total of 160 patients will be necessary (80 subjects
for each treatment group) to detect differences of at
least three points in the pain perception assessment
according to VAS (scale of 0 to 10). Accepted values will
be for an alpha risk of 1 % and beta risk of less than 5 %
in a bilateral contrast as well as a value of 4 for the
standard deviation (size effect of 0.75). It is assumed that
20 % of the trial patients will be lost to attrition. Patients
will be included in the study by case-consecutive, non-probability sampling after responding to a recruitment
visit to the Pain Clinic; then if they sign an informed
consent form, they will be placed randomly into one of
the treatment groups [30].
Inclusion criteria
Eligibility requirements will include the following: male
and female patients who are more than 50 years old
and who have knee OA diagnosed according to the
American College of Rheumatology classification cri-
teria (with at least one osteophyte in the tibiofemoral
joint and with a Kellgren-Lawrence grade of more than 2),
who have had a history of moderate or greater knee
pain of more than 3 months’ duration and have
reported moderate or greater, clinically significant,
knee pain during most days of the last month before
the interview, and who have given their consent to
participate in the study. Patients will be selected
among those who are not on the waiting list for total
knee arthroplasty by the traumatology unit of our
hospital.
Exclusion criteria
Patients with any of the following will be excluded
from the study: a history of any secondary OA associ-
ated with any systemic arthropathy (i.e., rheumatoid
arthritis or gouty arthritis); any knee treatment with
steroids, methotrexate, or azathioprine; recent trau-
matisms caused by acupunctural insertion; a history of
bleeding disorders or any disease related to acupunc-
ture contraindications; a history of any knee injection
in the previous 6 months (e.g., cortisone and hyalur-
onic acid); an acupuncture treatment history; or a his-
tory of morphine or morphine derivative use.
Removal criteria
Patients will be removed by voluntary removal or by failure
to consecutively attend two or more EA sessions.
Variables
Main variables
The primary outcomes will be the changes from the base-
line of the VAS and the Western Ontario and McMaster
Universities Osteoarthritis Index (WOMAC) for pain at the
completion of treatment at 12 weeks.
Secondary variables
Secondary variables to be considered are the following:
the change in the secondary efficacy variables from the
baseline of the Short Form 36 version 2 health survey
(SF-36v2) (patient-perceived quality of life), the change
in plasma cortisol and beta-endorphin levels, the scores
for the Goldberg Anxiety and Depression Scale (GADS),
Fig. 1 Trial flow. The study trial flow is described, indicating the patient selection process, treatment, and follow-up. *Visual analogue scale, Western Ontario
and McMaster Universities Osteoarthritis Index, Short Form 36 version 2 health survey, blood sample collection, Goldberg Anxiety and Depression Scale,
and medication use are measured on each follow-up visit. EA, Electro-acupuncture
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capacity and stiffness (WOMAC subscales), and VAS
scores measured at 1 month, 3 months, 6 months, and 1
year after study commencement.
Procedure
Figure 1 describes the trial protocol. The eligibility of
prospective participants will be determined by a re-
searcher who is not involved in the assessment or treat-
ment of the participants. Ethical approval was obtained
from the Balearic Islands Human Research Ethics Com-
mittee in July 2013 (CEI-IB, #IB 2077/13 PI).
Upon arrival at the Clinic for Pain Treatment, re-
cruited patients will be informed once again about the
trial objectives, and any questions or doubts that the
patient might still have with respect to the study will be
resolved. Patients will then be informed that they are
testing a new EA technique for knee pain treatment. Pla-
cebo or sham acupuncture (SA) will not be mentioned
to the patient during the interview or referred to in theinformed consent form. Subjects will be placed into one
of two study groups (with a strict 50 % probability), and
to reinforce and encourage treatment follow-up, patients
will be told that the effects are to be perceived over the
medium- to long-term time frame. Patients will be re-
assessed to ensure that they still comply with the selec-
tion criteria and that they have not acquired any new
criteria for exclusion. Participants will provide informed
consent in the first baseline visit (Table 1).
Baseline visit
The researcher will re-collect clinical data of patients,
including age, sex, and body mass index. In the baseline
interview, the participants will not yet be assigned to a
treatment group.
 Pain perception assessment will be based on (1) the
VAS score and (2) the WOMAC scale pain score.
The VAS is a continuous scale made up of a 10-cm,
unmarked, horizontal line, upon which the subject
Table 1 Planned visit schedule for treatment and follow-up, indicating visit number and frequency
Visits






















Explanation of the objectives of the
procedure and how it works
√
Informed consent √
Randomization and blinding √
Expectation of acupuncture √ √ √ √
Treatment
Electro-acupuncture (EA) √ √ √ √ √ √ √ √ √
Sham acupuncture (SA) √ √ √ √ √ √ √ √ √
Outcomes
Visual analogue scale (VAS) √ √ √ √ √
McMaster Universities Osteoarthritis
Index (WOMAC)
√ √ √ √ √
Medication use √ √ √ √ √
Goldberg Anxiety and Depression
Scale
√ √ √ √ √
Short Form Health Survey (SF-36v2) √ √ √ √ √
Blood sample collection √ √ √ √ √
Trial evaluation
Adverse event √ √ √ √
Outcome assessment √
Reasons of drop-outs or withdrawals √ √ √ √
Satisfaction and expectations Survey √
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pain felt; a mark on the far left of the line indicates
“no pain” (score of 0), and a mark to the far right
qualifies as “pain as bad as it could be” or “unbearable
pain” (score of 100). The WOMAC scale is used to
evaluate the condition of patients with OA of the
knee and the hip and includes pain, stiffness, and
physical functioning of the joints. This scale measures
five items for pain (with a score range of 0–20), two for
stiffness (score range of 0–8), and 17 for functional
limitation (score range of 0–68). The physical
functioning questions cover everyday activities.
These scales will be used separately and will not
be summed. Patients will respond orally to the five
levels with the following criteria: “none” = 0, “a
bit” = 1, “quite a bit” = 2, “a lot” = 3, and “very
much” = 4. If two or more questions are left
unanswered, the scale will be declared invalid. If
the patient does not respond to one question, amean will be taken from the results of the other
questions. The range will be 0–98.
 Analgesic medicine use. This questionnaire will have
four questions developed according the EUROHIS
(European Health Interview Survey)
recommendations in order to harmonize the
information regarding medicine use [31]. Subjects
will be asked (1) about the prescription medicine
their general practitioner may have prescribed for
them (“Have you taken any pain medicine
prescribed by your general practitioner?”) as well as
any medication not prescribed by their general
practitioner (“Have you taken any pain medicine not
prescribed by your general practitioner”) and (2)
whether or not their prescribed and non-prescribed
pain medication use has increased or decreased.
 The degree of functionality and stiffness according to
the WOMAC scale. There are two questions for
stiffness (scale of 0–8) and 17 questions for
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question will be answered orally with the following
criteria: “none” = 0, “a bit” = 1, “quite a bit” = 2, “a
lot” = 3, and “very much” = 4. If two or more
questions are unanswered, the scale scores will be
declared invalid and not counted.
 Anxiety/depression level according to the GADS.
This consists of two subscales (of nine questions for
each scale): an anxiety scale (1–9) and a depression
scale (10–18). The first questions for each scale
(1–4 and 10–13) are preconditioned questions to
determine whether the patient should attempt to
answer the rest of the questions of the two
subscales. Effectively, at least two questions must be
answered affirmatively in the first scale (1–4) for the
patient to continue; in the second scale, one answer
is sufficient for questions 10–13 for the patient to
continue with the rest of the questions. This study
will use the Spanish version validated by Montón
et al. [32].
 Degree of quality of life. This will be assessed
according to the SF-36v2 questionnaire and is
compounded by 36 items, which yield an 8-scale
profile of functional health and well-being scores as
well as psychometrically based physical and mental
health summary measures and a preference-based
health utility index. The Spanish version of the
SF-36 questionnaire by Ware and Sherbourne [33]
has been correctly translated and standardized and
has been given the Spanish title of Cuestionario de
Salud SF-36 [34].
The first baseline plasmatic sample will be extracted
from the antecubital vein to evaluate beta-endorphin
and cortisol levels, and the sampling time will be be-
tween 9 and 14 h. To avoid any diurnal variation in plas-
matic hormonal levels, subjects will always be assigned
the same hour for the extractions. Five blood samples (5
ml each) from each patient will be taken under aseptic
conditions from the antecubital vein; one extraction will
required before the treatment, one at 1 month after the
start of treatment, one at 3 months, one at 6 months,
and one at the end of treatment. Except for the first pre-
treatment sample, extractions will take place 5 min after
finishing the acupuncture treatment. Once extracted,
blood will be placed in a refrigerated tube with EDTA
(ethylenediaminetetraacetic acid) anticoagulant and cen-
trifuged immediately. Plasma will be extracted with a
micropipette and divided in two equal fractions (one for
the cortisol and one for the beta-endorphin analysis).
Samples will be stored at −70 °C until the analysis. The
baseline interview treatment will have no assigned sam-
pling time and will occur on the first day, when the sub-
ject is assigned to his or her respective treatment group.First day of treatment
Randomization
Each eligible patient will be randomly assigned to one of
two groups: “A” and “B”. A random number list gener-
ated by SPSS statistical software version 18.0 (IBM Cor-
poration, Armonk, NY, USA) (balanced for each six
cases per study branch) will be used for the allocation to
each group. Researchers from the statistical center will
send the randomized list in a numbered, sealed, and
opaque envelope to the researcher responsible for par-
ticipant recruitment and group assignment.
Blinding
The patient codes of the double-blind study will be
placed in numbered, sealed, and opaque envelopes.
Researchers, personnel performing the interviews, statisti-
cians, and participants will be blinded to patient allocation.
Study groups will consist of the following, although patients
will have no knowledge into which study branch they have
been placed: the experimental group (A) receiving EA or
the control group (B) receiving SA.
Intervention
The treatment will be applied in eight sessions (two per
week) for 1 month. Group A patients will receive the
EA treatment, and group B will receive the SA treat-
ment. Both groups will receive two weekly sessions for
4 weeks, then one session (each month) for the first
3 months, one session (each 45 days) until 6 months,
and finally one session every 2 months until finalizing
the study after a year’s time.
Treatments will be performed by the same acupuncturist,
an anesthesiology specialist who has studied Traditional
Chinese Medicine (TCM) at the University of Chinese
Medicine, Beijing, China, holds a master’s degree in acu-
puncture from the University of León, Spain, and has more
than 8 years of clinical experience in therapeutic pain man-
agement by acupuncture.
Experimental group (group A) EA will be performed
for a 20–30 min treatment session, and the patients will
be semi-seated comfortably on a stretcher. A 0.30 × 30
mm needle will be used and will make a 10–30 mm in-
sertion into the skin, depending on the patient’s consti-
tution. Needle insertion points will be selected according
to the TCM meridian theory for knee pain treatment.
Upon insertion, EA will be applied by a biphasic pulse
generator apparatus at a frequency of 3 Hz and at the
maximum tolerable intensity. Table 2 shows the local
and distal points: St 34 (Liáng Qiū), localized 2 cun
proximal to the upper lateral border of the patella, in a
groove of the vastus lateralis muscle; St 35 (Dú Bí), in
the depression inferior to the patella and lateral to the
patellar ligament; St 36 (Zú Sān Lĭ), one fingerbreadth
Table 2 Framework of acupuncture points that should be selected when administering acupuncture treatments
Location Acupuncture points Description
Local points
St 34 (Liáng Qiū) 2 cun proximal to the upper lateral border of the patella, in a groove of the vastus lateralis muscle.
St 35 (Dú Bí) In the depression inferior to the patella and lateral to the patellar ligament.
St 36 (Zú Sān Lĭ) One fingerbreadth lateral to the anterior crest of the tibia, on the tibialis anterior muscle.
Lv 8 (Qū Quán) Proximal to the medial end of the popliteal crease, in a depression anterior to the tendons of the
semitendinosus and semimembranosus muscles.
Sp 9 (Yīn Líng Quán) In a depression distal to the medial condyle of the tibia, at the junction of the shaft and the medial
condyle.
Sp 10 (Xuè Hăi) 2 cun proximal and slightly medial to the medial superior border of the patella, in a depression on
the vastus medialis muscle.
Ki 10 (Yīn Gŭ) At the medial end of the popliteal crease, between the tendons of the semimembranosus and
semitendinosus muscles, on the level of the knee joint space.
M-Le 16 (Xi Yan) Inferior to the patella, medial and lateral to the patellar ligament.
M-Le 27 (Hè Ding) In the center of the upper border of the patella.
Distal point
St 44 (Nèi Tíng) Between the second and third toes, proximal to the interdigital fold.
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anterior muscle; Lv 8 (Qū Quán), proximal to the medial
end of the popliteal crease, in a depression anterior to
the tendons of the semitendinosus and semimembrano-
sus muscles; Sp 9 (Yīn Líng Quán), in a depression distal
to the medial condyle of the tibia, at the junction of the
shaft and the medial condyle; Sp 10 (Xuè Hăi), 2 cun
proximal and slightly medial to the medial superior
border of the patella, in a depression on the vastus med-
ialis muscle; Ki 10 (Yīn Gŭ), at the medial end of the
popliteal crease, between the tendons of the semimem-
branosus and semitendinosus muscles, on the level of
the knee joint space; M-Le 16 (Xi Yan), inferior to the
patella, medial and lateral to the patellar ligament; and
M-Le 27 (Hè Ding), in the center of the upper border of
the patella. As a distal point, St 44 (Nèi Tíng), between
the second and third toes, proximal to the interdigital
fold, will be used.
The needles will be inserted through the same guide tube
that will be used for the control group. The objective is for
control patients to perceive the De-Qi sensation, which is
like a tingling or numbness on the specific points punc-
tured. Subsequently, EA will be used between Xiyan points
and also to the points that the patient recalls as the area of
pain. If both knees are affected, the same acupuncture
points will be applied.
To ensure that the treatment procedures for the treat-
ment and the control groups are as similar as possible, we
will tape two guide tubes to two sham points at the ab-
dominal area, approximately 3 cm lateral to and slightly
above the umbilicus bilaterally. Immediately after, we will
affix a pair of needles by adhesive tape to the surface at
these same points though without needle insertion. This
site was chosen for two reasons. First, these sites were attwo meridians that are theoretically irrelevant to knee
pain. Second, to facilitate blinding, we wanted to provide
the participants of both groups the opportunity to be able
to feel a sensation similar to the actual insertion of the
needle.
Control group (group B) A valid method of placebo
acupuncture with non-insertion of the needle will be
used for the control group [35]. Two needles will be
inserted into the sham points of the abdominal area in
the same position used for group A, approximately 3 cm
lateral to and slightly above the umbilicus bilaterally,
and then two pieces of adhesive tape will be immediately
taped next to the needles. In addition, a mock plastic
needle guide tube will be placed on the surface of each
of the nine true points in the leg so that some discern-
able sensation will be produced; then a needle will be
immediately applied without needle insertion to the der-
mal surface at each point and will be retained at this
position for 20–30 min. These plastic guide tubes will be
applied in the same manner as for group A in order to
produce the same perceptible sensation.
The control group will receive the same session and
schedule as group A. This will include the same active
needle placements, although needle insertion will not
occur at these nine points (local and distal points). Not
only will the accessories of the EA equipment be con-
nected in the same point in group A without electric
stimulation, a mock transelectrical stimulation unit
(which emits a “timer” sound and has a blinking light)
will be attached to the sham needles at the knee.
To facilitate patient blinding for both groups, a screen
will be placed below the abdomen to prevent partici-
pants from actually observing true or sham procedures
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to see the procedure that is being given in the abdominal
area. It is important to state that this type of interven-
tion will need some time for the results to be noted, and
a thorough follow-up is necessary to avoid dropouts
from both groups.
Next several visits for treatment (two sessions per week
until the completion of eight sessions)
The same treatment will be repeated according to group.
In the last session, blood samples will be drawn 5 min
after the treatment completion, at the same time of day
as the previous extraction.
At 1 month’s time
The interviewers will repeat the assessments for pain level,
analgesic consumption, and the type of treatment that the
patient believes he or she is receiving as well as the assess-
ment by the WOMAC scale and the GADS. The patient
will once again answer the quality-of-life questionnaire
(SF-36v2). Once the forms have been completed, treat-
ment will be administered to the patient.
Subsequent visits
At 3 and 6 months after treatment start and at the final
visit, the questionnaires again will be filled out. The in-
terviewers will also note EA-related adverse effects or
complications observed either by the participants or by
the acupuncturist throughout the duration of the treat-
ment. Treatments will be performed each month up
until the third month, and after this latter treatment ses-
sion, with just one treatment every 45 days until the
sixth month. Finally, a treatment will occur every 2
months until the study is completed at the end of 1 year.
Blood tests will be performed again on the third month,
on the sixth month, and at the end of treatment period.
Study end
At study completion, a questionnaire will be given that
includes questions related to patient satisfaction with
the treatment received, the type of treatment patients
believe they have received, and their expectations for
improvement.
Statistical analysis
The results will be analyzed by using the SPSS statistical
software version 18.0. A descriptive analysis of the col-
lected data will be obtained by using the mean, the
standard deviation, and the maximum and minimum
values for the quantitative variables that follow a normal
distribution. For variables without a normal distribution
(degree of pain, plasma levels, and quality of life, among
others), the median, the 25th and 75th percentiles, and
maximum and minimum values will be calculated.Qualitative variables will be expressed as frequencies
and percentages. Differences shall be detected by chi-
square or Fisher tests for categorical variables and Stu-
dent t or Mann-Whitney tests for the resultant variables.
Discussion
The aim of the study is to measure the effectiveness of
EA in alleviating OA knee pain. Effectiveness indicators
should be the relief of pain, stiffness and functional dis-
ability of the knee, the improvement of quality of live
and a reduction in medication use.
The principal challenge expected with this study is the
difficulty of effectively blinding SA application in a man-
ner that is believable or credible for the patient. For this
reason, we will avoid using the terms “sham acupunc-
ture” or “placebo” in the information letter and consent
form. The attempt to blind the process will be done by
explaining to the patient that a new pain treatment will
be assessed and compared with other techniques (infil-
trations and analgesic stimulation) and that the selected
patients must have no history of acupuncture treatment.
The literature reports that the non-penetrating SA
method has been widely used and has also been vali-
dated for avoiding skin receptor stimulation in SA [36].
Disclosure of a patient’s group affiliation will be avoided
so that they will not be able to share information among
themselves or compare treatments. The only person who
will have full knowledge of the applied treatment will be
the acupuncturist, although he will remain blind to the
rest of the details of the study.
A satisfaction questionnaire will be completed at the
end of the study to assess whether the patients believe
they have or have not received treatment. To avoid
introducing bias that could be caused by the interference
of the circadian rhythm in the beta-endorphin and corti-
sol levels, patients will always be scheduled for blood
sampling at the same hour.
As has been shown, it would seem clear that the treat-
ment of knee OA must be a multidisciplinary approach,
as there is currently no treatment alone that may be
considered beneficial in absolute terms.
Although there are studies showing the efficacy of acu-
puncture for the treatment of OA pain, the lack of a
common methodology to apply the treatment design
complicates the comparison of the results between
studies.
In this article, we combine all of the methodological
suggestions for acupuncture studies, attempting to
minimize the biases that may result from study design.
We intend to make a comparison with a placebo that
would allow the hypothesis to be validated.
We must not forget the current economic circum-
stances that drive us to look for therapies that are cost-
beneficial for both the patient and the health system. In
Mata et al. Trials  (2015) 16:248 Page 9 of 10this direction, there are studies that suggest acupuncture
as a cost-effective therapy for the treatment of knee OA.
Finally, sufficient evidence about the different physio-
logical mechanisms would encourage further research
on how acupuncture can relieve pain. However, the ef-
fect of acupuncture on the HPA system is not clear, and
therefore we intend to provide more information that
would clarify its function.
Trial status
The trial is currently in the recruitment phase. Partici-
pant recruitment started in January 2015 and is expected
to end in December 2015.
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